Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pseudomyxoma peritonei

P H Sugarbaker1

  • 1Cancer Institute, Washington Hospital Center, DC 20010, USA.

Cancer Treatment and Research
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Pseudomyxoma peritonei, a rare cancer originating in the appendix, involves tumor spread within the abdomen. Modern treatments offer significantly improved long-term survival rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2018
Same author

Increased safety of surgical glove application: the under/over method.

Annals of the Royal College of Surgeons of England·2017
Same author

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2017
Same author

Management of an inguinal hernia in patients with pseudomyxoma peritonei.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2017
Same author

Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016
Same author

A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Pseudomyxoma peritonei (PMP) presents diagnostic and therapeutic challenges.
  • It is characterized by mucinous adenocarcinoma, often originating from an appendiceal adenoma.
  • PMP involves tumor cell redistribution within the abdomen and pelvis, sparing the small bowel.

Purpose of the Study:

  • To clarify the etiology, clinical manifestations, treatment, and prognosis of pseudomyxoma peritonei.
  • To highlight the importance of early diagnosis and intervention.
  • To evaluate the efficacy of modern therapeutic approaches.

Main Methods:

  • Review of clinical data and treatment outcomes for pseudomyxoma peritonei.
  • Analysis of the "redistribution phenomenon" characteristic of PMP.
  • Evaluation of outcomes with traditional surgical procedures versus modern peritoneotomy and intraperitoneal chemotherapy.

Related Experiment Videos

Main Results:

  • Traditional surgical treatment yields a median survival of approximately 2 years.
  • Early diagnosis and treatment are crucial to prevent complications like small bowel entrapment.
  • Modern therapy with peritoneotomy and intraperitoneal chemotherapy (mitomycin C, 5-fluorouracil) shows a 10-year survival approaching 80%.

Conclusions:

  • Pseudomyxoma peritonei requires a thorough understanding of its unique spread patterns.
  • Aggressive surgical management combined with targeted intraperitoneal chemotherapy significantly improves patient survival.
  • The prognosis for PMP has dramatically improved with advancements in treatment modalities.